Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Her2-Positive Breast Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT05075512
What this trial is testing

The Efficacy and Safety of Anlotinib Combined With Fulvestrant in Patients With Advanced Breast Cancer

Who this might be right for
Breast Neoplasm Female
Zhejiang Cancer Hospital 40
Testing effectiveness (Phase 2)Looking for participantsNCT06837792
What this trial is testing

Trastuzumab Deruxtecan vs Endocrine Therapy in Low-HER2 HR+ Advanced Breast Cancer

Who this might be right for
Hormone Receptor(HR)-Positive, Low HER2 Advanced Breast Cancer Patients (HER2 IHC 1+ or 2+ & ISH Negative)
Yonsei University 141
Testing effectiveness (Phase 2)Study completedNCT00347919
What this trial is testing

Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Advanced Or Metastatic Breast Cancer

Who this might be right for
Neoplasms, Breast
GlaxoSmithKline 189
Testing effectiveness (Phase 2)Looking for participantsNCT04090567
What this trial is testing

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

Who this might be right for
Advanced Breast CarcinomaAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IIIA Breast Cancer AJCC v8+12 more
M.D. Anderson Cancer Center 60
Early research (Phase 1)Ended earlyNCT05384119
What this trial is testing

Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer

Who this might be right for
Breast Cancer
Tvardi Therapeutics, Incorporated 6
Large-scale testing (Phase 3)Looking for participantsNCT07207070
What this trial is testing

A Randomised, Open-label, Multicentre Phase III Clinical Study to Evaluate the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestrant Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutated, HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer.

Who this might be right for
Breast Cancer
Risen (Suzhou) Pharma Tech Co., Ltd. 312
Testing effectiveness (Phase 2)Study completedNCT05549505
What this trial is testing

A Trial Using ARV-471 or Anastrozole in Post-Menopausal Women With Breast Cancer Prior to Surgery

Who this might be right for
Breast Cancer
Arvinas Inc. 152
Not applicableLooking for participantsNCT06894173
What this trial is testing

EvoLution of Neoadjuvant TreatMent in 'Triple-negative' or 'HER-2-positive' Breast Cancer Diagnosed in the EaRly Phase

Who this might be right for
Breast Cancer
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 1,000
Testing effectiveness (Phase 2)Looking for participantsNCT06441890
What this trial is testing

BRE-10: Biomarker Optimization of Neoadjuvant Therapy in Breast Cancer

Who this might be right for
Breast CancerHER2-positive Breast Cancer
University of Illinois at Chicago 28
Testing effectiveness (Phase 2)Ended earlyNCT04789096
What this trial is testing

Tucatinib Together With Pembrolizumab and Trastuzumab

Who this might be right for
Breast CancerHER2-positive Breast Cancer
Breast Cancer Trials, Australia and New Zealand 31
Testing effectiveness (Phase 2)Study completedNCT03530696
What this trial is testing

T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer

Who this might be right for
HER2-positive Breast CancerBreast CancerBreast Cancer Stage+3 more
University of Arizona 55
Testing effectiveness (Phase 2)Study completedNCT01271920
What this trial is testing

Combination of AUY922 With Trastuzumab in HER2+ Advanced Breast Cancer Patients Previously Treated With Trastuzumab

Who this might be right for
Advanced HER2-positive Breast Cancer
Novartis Pharmaceuticals 45
Testing effectiveness (Phase 2)Study completedNCT01989780
What this trial is testing

Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer

Who this might be right for
Metastatic Breast Cancer
Japan Breast Cancer Research Group 160
Not applicableNot Yet RecruitingNCT07593196
What this trial is testing

HER2-positive Metastatic Breast Cancer in Kazakhstan

Who this might be right for
Metastatic Breast Cancer
AstraZeneca 240
Large-scale testing (Phase 3)Active Not RecruitingNCT05654623
What this trial is testing

Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

Who this might be right for
Advanced Breast Cancer
Pfizer 624
Not applicableActive Not RecruitingNCT06735742
What this trial is testing

Learn About the Safety of TALZENNA for the Treatment of Breast Cancer

Who this might be right for
Breast Cancer
Pfizer 3
Testing effectiveness (Phase 2)Ended earlyNCT02067741
What this trial is testing

CR1447 in Endocrine Responsive-HER2neg and TN-ARpos Breast Cancer

Who this might be right for
Metastatic Breast AdenocarcinomaBreast Cancer
Swiss Cancer Institute 29
Testing effectiveness (Phase 2)Study completedNCT01674062
What this trial is testing

Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) in Participants With Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 95
Testing effectiveness (Phase 2)Looking for participantsNCT06374459
What this trial is testing

Zunsemetinib in Combination With Capecitabine in Patients With Hormone Receptor-Positive and HER2-Negative Metastatic Breast Cancer With Bone Metastasis

Who this might be right for
Hormone Receptor Positive HER-2 Negative Metastatic Breast Cancer
Washington University School of Medicine 152
Testing effectiveness (Phase 2)WithdrawnNCT01137994
What this trial is testing

A Phase II, Randomized, Open-label Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy in HER2-positive and p95HER2-positive Metastatic Breast Cancer

Who this might be right for
Neoplasms, Breast
GlaxoSmithKline
Next Page